Is a Novel Driver of Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer and Is Selectively Released in Extracellular Vesicles with

Overview

Journal Clin Cancer Res

Specialty Oncology

Date 2019 Aug 3

PMID 31371344

Citations 44

Authors

Divya Bhagirath

Thao Ly Yang

Z Laura Tabatabai

Shahana Majid

Rajvir Dahiya

Yuichiro Tanaka

Sharanjot Saini

Affiliations

Soon will be listed here.

Abstract

Purpose: Neuroendocrine prostate cancer (NEPC), an aggressive variant of castration-resistant prostate cancer (CRPC), often emerges after androgen receptor-targeted therapies such as enzalutamide or , via trans-differentiation process of neuroendocrine differentiation. The mechanistic basis of neuroendocrine differentiation is poorly understood, contributing to lack of effective predictive biomarkers and late disease recognition. The purpose of this study was to examine the role of novel proneural it-ct-nc-domain transcription factors (TF) in NEPC and examine their potential as noninvasive predictive biomarkers. Prostate cancer patient-derived xenograft models, clinical samples, and cellular neuroendocrine differentiation models were employed to determine the expression of TFs and . levels were modulated in prostate cancer cell lines followed by functional assays. Furthermore, extracellular vesicles (EV) were isolated from patient samples and cell culture models, characterized by nanoparticle tracking analyses, Western blotting, and real-time PCR.

Results: We identify for the first time that: (i) is amplified and overexpressed in NEPC clinical samples and that overexpression drives neuroendocrine differentiation via its interplay with , a TF that was previously implicated in NEPC; (ii) and mRNA are actively released in prostate cancer EVs upon neuroendocrine differentiation induction; and (iii) enzalutamide treatment augments release of and in prostate cancer EVs, promoting neuroendocrine differentiation induction.

Conclusions: Our study identifies a novel TF that drives NEPC and suggests that as adaptive mechanism to enzalutamide treatment, prostate cancer cells express and secrete and in EVs that drive oncogenic reprogramming of prostate cancer cells to NEPC. Importantly, EV-associated and are potential novel noninvasive biomarkers to predict neuroendocrine differentiation in CRPC.

Citing Articles

Small cell lung cancer and prostate cancer cells with varying neuroendocrine differentiation markers show sensitivity to imipridone ONC201/TIC10.

Ding E, Pinho-Schwermann M, Zhang S, Purcell C, El-Deiry W Am J Transl Res. 2025; 17(1):104-115.

PMID: 39959215 PMC: 11826210. DOI: 10.62347/IBUS3598.

Investigating POU3F4 in cancer: Expression patterns, prognostic implications, and functional roles in tumor immunity.

Chen W, Ji Y, Wang R, Ji R, Lin Y, Wu Y Heliyon. 2025; 11(1):e41587.

PMID: 39866492 PMC: 11760290. DOI: 10.1016/j.heliyon.2024.e41587.

Therapeutic Exploitation of Neuroendocrine Transdifferentiation Drivers in Prostate Cancer.

Maylin Z, Smith C, Classen A, Asim M, Pandha H, Wang Y Cells. 2024; 13(23).

PMID: 39682746 PMC: 11639977. DOI: 10.3390/cells13231999.

The neuroendocrine transition in prostate cancer is dynamic and dependent on ASCL1.

Romero R, Chu T, Gonzalez Robles T, Smith P, Xie Y, Kaur H Nat Cancer. 2024; 5(11):1641-1659.

PMID: 39394434 PMC: 11584404. DOI: 10.1038/s43018-024-00838-6.

The biological function of extracellular vesicles in prostate cancer and their clinical application as diagnostic and prognostic biomarkers.

Limonta P, Marchesi S, Giannitti G, Casati L, Fontana F Cancer Metastasis Rev. 2024; 43(4):1611-1627.

PMID: 39316264 PMC: 11554767. DOI: 10.1007/s10555-024-10210-w.

References

Knudsen K, Scher H . Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. Clin Cancer Res. 2009; 15(15):4792-8. PMC: 2842118. DOI: 10.1158/1078-0432.CCR-08-2660. View

Aggarwal R, Huang J, Alumkal J, Zhang L, Feng F, Thomas G . Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. J Clin Oncol. 2018; 36(24):2492-2503. PMC: 6366813. DOI: 10.1200/JCO.2017.77.6880. View

Rotinen M, You S, Yang J, Coetzee S, Reis-Sobreiro M, Huang W . ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis. Nat Med. 2018; 24(12):1887-1898. PMC: 6614557. DOI: 10.1038/s41591-018-0241-1. View

Watson P, Arora V, Sawyers C . Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer. 2015; 15(12):701-11. PMC: 4771416. DOI: 10.1038/nrc4016. View

Siegel R, Miller K, Jemal A . Cancer statistics, 2019. CA Cancer J Clin. 2019; 69(1):7-34. DOI: 10.3322/caac.21551. View

Hessvik N, Sandvig K, Llorente A . Exosomal miRNAs as Biomarkers for Prostate Cancer. Front Genet. 2013; 4:36. PMC: 3604630. DOI: 10.3389/fgene.2013.00036. View

Beltran H, Tomlins S, Aparicio A, Arora V, Rickman D, Ayala G . Aggressive variants of castration-resistant prostate cancer. Clin Cancer Res. 2014; 20(11):2846-50. PMC: 4040316. DOI: 10.1158/1078-0432.CCR-13-3309. View

Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee J, Lotvall J . Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007; 9(6):654-9. DOI: 10.1038/ncb1596. View

Lotan T, Gupta N, Wang W, Toubaji A, Haffner M, Chaux A . ERG gene rearrangements are common in prostatic small cell carcinomas. Mod Pathol. 2011; 24(6):820-8. PMC: 3484363. DOI: 10.1038/modpathol.2011.7. View

10.

Sobol S, Teng X, Crenshaw 3rd E . Abnormal mesenchymal differentiation in the superior semicircular canal of brn4/pou3f4 knockout mice. Arch Otolaryngol Head Neck Surg. 2005; 131(1):41-5. DOI: 10.1001/archotol.131.1.41. View

11.

Valentino A, Reclusa P, Sirera R, Giallombardo M, Camps C, Pauwels P . Exosomal microRNAs in liquid biopsies: future biomarkers for prostate cancer. Clin Transl Oncol. 2017; 19(6):651-657. DOI: 10.1007/s12094-016-1599-5. View

12.

Yuan T, Veeramani S, Lin F, Kondrikou D, Zelivianski S, Igawa T . Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells. Endocr Relat Cancer. 2006; 13(1):151-67. DOI: 10.1677/erc.1.01043. View

13.

Skog J, Wurdinger T, van Rijn S, Meijer D, Gainche L, Sena-Esteves M . Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 2008; 10(12):1470-6. PMC: 3423894. DOI: 10.1038/ncb1800. View

14.

Lai S, Brauch H, Knutsen T, Johnson B, Nau M, Mitsudomi T . Molecular genetic characterization of neuroendocrine lung cancer cell lines. Anticancer Res. 1995; 15(2):225-32. View

15.

Maina P, Shao P, Liu Q, Fazli L, Tyler S, Nasir M . c-MYC drives histone demethylase PHF8 during neuroendocrine differentiation and in castration-resistant prostate cancer. Oncotarget. 2016; 7(46):75585-75602. PMC: 5342763. DOI: 10.18632/oncotarget.12310. View

16.

Aggarwal R, Small E . Small-cell/neuroendocrine prostate cancer: a growing threat?. Oncology (Williston Park). 2014; 28(10):838-40. View

17.

Thery C, Zitvogel L, Amigorena S . Exosomes: composition, biogenesis and function. Nat Rev Immunol. 2002; 2(8):569-79. DOI: 10.1038/nri855. View

18.

Culig Z . Molecular Mechanisms of Enzalutamide Resistance in Prostate Cancer. Curr Mol Biol Rep. 2017; 3(4):230-235. PMC: 5700216. DOI: 10.1007/s40610-017-0079-1. View

19.

Nicola A, Frases S, Casadevall A . Lipophilic dye staining of Cryptococcus neoformans extracellular vesicles and capsule. Eukaryot Cell. 2009; 8(9):1373-80. PMC: 2747831. DOI: 10.1128/EC.00044-09. View

20.

Soekmadji C, Corcoran N, Oleinikova I, Jovanovic L, Ramm G, Nelson C . Extracellular vesicles for personalized therapy decision support in advanced metastatic cancers and its potential impact for prostate cancer. Prostate. 2017; 77(14):1416-1423. DOI: 10.1002/pros.23403. View